

Supplementary Table 1: Classification of antibiotics.

Antibiotic classes	ATC code	Name
Azole antifungals	J02AC01	fluconazole
	J02AC02	itraconazole
Other antifungals	J02AA01	amphotericin B
	J02AX01	flucytosine
Macrolides	J01FA01	erythromycin
	J01FA02	spiramycin
	J01FA03	midecamycin
	J01FA06	roxithromycin
	J01FA07	josamycin
	J01FA09	clarithromycin
	J01FA10	azithromycin
	J01FA15	telithromycin
Metronidazole based-antibiotherapies	J01RA04	spiramycin et metronidazole
	P01AB01	metronidazole
Quinolones	J01MA01	ofloxacin
	J01MA02	ciprofloxacin
	J01MA03	pefloxacin
	J01MA04	enoxacin
	J01MA06	norfloxacin
	J01MA07	lomefloxacin
	J01MA12	levofloxacin
	J01MA14	moxifloxacin
	J01MB04	pipemidic acid
	J01MB07	flumequine
Streptogramins	J01FG01	pristinamycin
Penicillin A	J01CA04	amoxicillin
Penicillin A and beta-lactamase inhibitors	J01CR01	ampicillin and beta-lactamase inhibitor
	J01CR02	amoxicillin and beta-lactamase inhibitor
Cephalosporins (third generation)	J01DD02	ceftazidime
	J01DD04	ceftriaxone
	J01DD08	cefixime
	J01DD13	cefpodoxime
	J01DE01	cefepime
Other beta-lactamines	J01CA08	pivmecillinam
	J01CE02	phenoxymethylpenicillin
	J01CE08	benzathine benzylpenicillin
	J01CF02	cloxacillin
	J01CF04	oxacillin

J01CR03	ticarcillin and beta-lactamase inhibitor
J01CR05	piperacillin and beta-lactamase inhibitor
J01DB01	cefalexin
J01DB05	cefadroxil
J01DC02	cefuroxime
J01DC04	cefaclor
J01DC07	cefotiam
J01DF01	aztreonam
J01DH02	meropenem
J01DH51	imipenem and cilastatin

Other antibiotics

J01AA02	doxycycline
J01AA05	metacycline
J01AA07	tetracycline
J01AA08	minocycline
J01BA02	thiamphenicol
J01EE01	sulfamethoxazole and trimethoprim
J01FF01	clindamycin
J01FF02	lincomycin
J01GB01	tobramycin
J01GB07	netilmicin
J01XB01	colistin
J01XC01	fusidic acid
J01XE01	nitrofurantoin
J01XX01	fosfomycin
J04AB02	rifampicin
J04AB04	rifabutin
J04AC01	isoniazid
J04AK01	pyrazinamide
J04AK02	ethambutol
J04AM02	rifampicin and isoniazid

Supplementary Table 2. Description of most frequently prescribed antibiotic combinations (other than other) in patients who received several antibiotics (n=13 669).

ATB Combinations	n	%
Penicillin A and beta-lactamase inhibitors + Quinolones	625	4.6
Penicillin A + Penicillin A and beta-lactamase inhibitors	505	3.7
Metronidazole based-antibiotherapies + Quinolones	450	3.3
Penicillin A + Quinolones	449	3.3
Penicillin A and beta-lactamase inhibitors + Metronidazole based-antibiotherapies	376	2.8
Cephalosporins (third generation) + Quinolones	344	2.6
Penicillin A + Macrolides	321	2.4
Cephalosporins (third generation) + Penicillin A and beta-lactamase inhibitors + Quinolones	289	2.2
Cephalosporins (third generation) + Penicillin A Quinolones	282	2.1
Penicillin A + Macrolides + Metronidazole based-antibiotherapies	260	1.9
Other combinations	9 768	71.5

Supplementary Table 3. Infections requiring antibiotics at hospital during the perioperative period (n= 13 319 patients).

	Within 6 months before surgery	During surgical resection stay	1-30 days after surgery	31-90 days after surgery	91 days-1 year after surgery	Total	
	n	n	n	n	n	n	%
Bacteremias	158	854	116	126	316	1 471	11.0
Digestive infections	1 429	3 368	555	406	632	5 574	41.8
Post-surgical site infections	132	3 800	672	563	642	5 125	38.5
Respiratory infections	310	1 190	188	206	542	2 201	16.5
Urinary infections	81	170	48	101	135	504	3.8
Bone infections	38	9	4	18	29	86	0.6
Cutaneous infections	65	105	18	20	70	265	2.0
Not specified infections	345	1 979	124	155	257	2 270	17.0
Total *	2 576	9 540	1 294	1 377	2 300	13 326	100

*One patient may have multiple infections thus the total is not necessarily equal to the sum of all patients.

Supplementary table 4. Pre- and post resection exposure to antibiotics per class in the cohort of patients with resected colorectal cancer.

	Period	Number of patients	Number of days	% of days of the period	Nb of patients with microbiota impact during chemo	Number of days with microbiota impact during chemo	% of days with microbiota impact during chemo
		n	median (q1-q3)	median (q1-q3)	n	median (q1-q3)	median (q1-q3)
Global	Pre resection	13 779	43 (34-61)	24 (19-34)	1 261	28 (16-40)	61 (34-92)
Global	Post resection	21 601	55 (39-95)	18 (11-30)	5 112	45 (31-76)	33 (20-56)
C3G	Pre resection	1 755	36 (32-39)	20 (18-22)	110	20 (10-30)	40.5 (23-69)
C3G	Post resection	3 109	36 (33-41)	10 (9-13)	494	35 (24-39)	21 (15-26)
Antifungal – Azoles	Pre resection	459	34 (31-38)	19 (17-21)	103	26 (17-33)	51 (31-74)
Antifungal – Azoles	Post resection	1 531	34 (32-50)	10 (9-18)	804	34 (30.5-57.5)	23 (18-42)
Antifungal – Others	Pre resection	559	38 (33-47)	21 (18-26)	195	32 (25-42)	64 (37-93)
Antifungal – Others	Post resection	2 252	40 (34-64)	12 (10-21)	1 436	39 (32-69)	29 (20-52)
Beta-lactamines – Others	Pre resection	691	38 (33-42)	21 (18-23)	33	21 (15-29)	57 (33-81)
Beta-lactamines – Others	Post resection	1 445	39 (35-45)	11 (10-14)	250	38 (27-46)	23 (16-36)
Penicillin A	Pre resection	3 815	43 (35-49)	24 (19-28)	260	25 (15-36)	54 (28-84)
Penicillin A	Post resection	6 556	45 (39-55)	12 (11-16)	1 031	43 (31-49)	26 (19-33)
Penicillin A + beta-lactamase inhibitor	Pre resection	3 229	46 (31-55)	26 (17-31)	301	30 (16-41)	55 (34-89)
Penicillin A + beta-lactamase inhibitor	Post resection	7 132	52 (42-58)	15 (12-20)	1 649	42 (22-54)	27 (16-35)
Macrolides	Pre resection	2 171	36 (31-41)	20 (17-23)	120	24 (15-31.5)	53 (28.5-81.5)
Macrolides	Post resection	3 015	36 (33-41)	10 (9-12)	358	36 (23-41)	21 (14-26)
Metronidazole based-antibiotherapies	Pre resection	2 933	33 (21-37)	18 (12-21)	161	21 (12-30)	41 (25-65)

Metronidazole based- antibiotherapies	Post resection	3 910	34 (29-38)	9 (8-11)	440	27 (12-34)	17 (9-21)
Quinolones	Pre resection	3 286	37 (33-43)	21 (19-24)	347	25 (13-36)	43 (25-69)
Quinolones	Post resection	7 342	40 (36-46)	11 (10-17)	1 579	35 (18-41)	22 (13-30)
Streptogramins	Pre resection	858	39 (35-42)	22 (19-24)	47	26 (11-38)	45 (23-73)
Streptogramins	Post resection	1 606	39 (36-43)	11 (10-13)	251	37 (23-42)	22 (14-27)
Other ATB including cyclins	Pre resection	1 707	36 (31-52)	20 (17-29)	168	32.5 (12.5-59.5)	51.5 (26-84)
Other ATB including cyclins	Post resection	3 387	38 (32-59)	11 (9-19)	591	36 (22-61)	24 (16-45)
Infections needing hospitalization	Pre resection	2 557	7 (1-14)	4 (1-8)	60	10.5 (6-16.5)	17.5 (8.5-44)
Infections needing hospitalization	Post resection	11 901	18 (12-30)	6 (4-13)	455	8 (3-15)	7 (3-32)

Supplementary table 5. Days of adjuvant chemotherapy with antibiotic intake or impact on the microbiota.

How to read the table: 409 patients (4.4% of patients with adjuvant chemotherapy) had between 1 and 9% of their chemotherapy period time with an impact on microbiota related to any ATB.

Days	ATB as outpatient (all ATB)		C3G		Antifungal - Other		Antifungal Azoles		Other betalactamines		Penicillin A		Penicillin A + beta-lactamase inhibitors		Macrolides		Metronidazole based-ATB		Quinolones		Streptogramins		Other ATB including cyclins	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
0	4 123	44.7	8 738	94.6	7 797	84.5	8 428	91.3	8 982	97.3	8 203	88.9	7 584	82.1	8 875	96.1	8 795	95.3	7 655	82.9	8 982	97.3	8 641	93.6
01-09	409	4.4	67	0.7	70	0.8	44	0.5	31	0.3	111	1.2	213	2.3	48	0.5	115	1.2	265	2.9	32	0.3	84	0.9
10-19	731	7.9	144	1.6	254	2.8	223	2.4	62	0.7	153	1.7	328	3.6	94	1.0	153	1.7	389	4.2	67	0.7	128	1.4
20-29	1 085	11.8	176	1.9	400	4.3	231	2.5	83	0.9	393	4.3	432	4.7	161	1.7	107	1.2	517	5.6	98	1.1	134	1.5
30-39	789	8.5	39	0.4	189	2.0	89	1.0	16	0.2	209	2.3	337	3.7	26	0.3	27	0.3	136	1.5	20	0.2	70	0.8
40-49	547	5.9	32	0.3	144	1.6	56	0.6	9	0.1	67	0.7	112	1.2	8	0.1	19	0.2	102	1.1	14	0.2	39	0.4
50-59	392	4.2	13	0.1	89	1.0	48	0.5	4	0.0	41	0.4	60	0.6	4	0.0	3	0.0	53	0.6	5	0.1	31	0.3
60-69	310	3.4	7	0.1	69	0.7	26	0.3	2	0.0	25	0.3	50	0.5	6	0.1	4	0.0	30	0.3	4	0.0	19	0.2
70-79	218	2.4	7	0.1	54	0.6	15	0.2	3	0.0	4	0.0	26	0.3	1	0.0	2	0.0	19	0.2	3	0.0	18	0.2
80-89	164	1.8	2	0.0	39	0.4	14	0.2	7	0.1	8	0.1	20	0.2	3	0.0	2	0.0	10	0.1	1	0.0	20	0.2
90-100	464	5.0	7	0.1	127	1.4	58	0.6	33	0.4	18	0.2	70	0.8	6	0.1	5	0.1	56	0.6	6	0.1	48	0.5

Supplementary Table 6. Multivariate analyses for 3-year DFS in patients with resected colorectal cancer according to antibiotic and chemotherapy exposure.

6A-Localized colon cancer patients (n=17,335)

Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.152	1.092	1.215
Age	50 to 69 vs <50	0.0950	1.146	0.977	1.344
	70-79 vs <50	<.0001	1.444	1.230	1.695
	≥ 80 vs <50	<.0001	2.276	1.946	2.663
Charlson	1 à 2 vs 0	<.0001	1.144	1.077	1.215
	≥ 3 vs 0	<.0001	1.569	1.459	1.688
Malnutrition	Yes vs No	<.0001	1.363	1.273	1.459
ICU stay	> 2 to 7 days vs 0-2 days	<.0001	1.485	1.330	1.657
	> 7 days vs 0-2 days	<.0001	2.196	1.987	2.428
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.9665	0.999	0.944	1.057
ATB with hospitalization	Yes vs No	0.8671	1.008	0.920	1.104
<i>Post resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.1471	1.045	0.985	1.108
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.614	1.524	1.709
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	2.341	2.058	2.663
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.151	1.091	1.214
Age	50 to 69 vs <50	0.1026	1.142	0.974	1.341
	70-79 vs <50	<.0001	1.443	1.229	1.694
	≥ 80 vs <50	<.0001	2.272	1.941	2.658
Charlson	1 à 2 vs 0	<.0001	1.141	1.074	1.212
	≥ 3 vs 0	<.0001	1.559	1.450	1.678
Malnutrition	Yes vs No	<.0001	1.361	1.272	1.457
ICU stay	> 2 to 7 days vs 0-2 days	<.0001	1.483	1.328	1.656
	> 7 days vs 0-2 days	<.0001	2.208	1.997	2.441
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.6928	0.989	0.934	1.046
ATB with hospitalization	Yes vs No	0.7395	1.016	0.927	1.113
<i>Post resection ATB exposure</i>					
C3G	Yes vs No	0.5794	1.028	0.932	1.135
Antifungal – Others	Yes vs No	0.0010	1.311	1.115	1.542
Antifungal – Azoles	Yes vs No	0.0468	1.190	1.002	1.412
Beta-lactamines – Others	Yes vs No	0.7243	1.026	0.890	1.183
Penicillin A	Yes vs No	0.4513	0.970	0.896	1.050
Penicillin A + beta-lactamase inhibitor	Yes vs No	0.0097	1.102	1.024	1.186

Macrolides	Yes vs No	0.0344	0.887	0.794	0.991
Metronidazole based-antibiotherapies	Yes vs No	0.6903	1.021	0.923	1.128
Quinolones	Yes vs No	0.2057	1.049	0.974	1.129
Streptogramins	Yes vs No	0.0070	1.197	1.050	1.365
Other ATB including cyclins	Yes vs No	0.5505	1.031	0.933	1.140
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.590	1.501	1.685
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	2.266	1.990	2.581

6B-Advanced colon cancer patients (n=5,805)

Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.227	1.129	1.333
Age	50 to 69 vs <50	0.8100	1.019	0.877	1.183
	70-79 vs <50	0.3136	1.085	0.926	1.273
	≥ 80 vs <50	<.0001	1.478	1.235	1.769
Charlson	1 à 2 vs 0	0.3566	1.047	0.950	1.153
	≥ 3 vs 0	0.0601	1.171	0.993	1.381
Malnutrition	Yes vs No	0.0057	1.183	1.050	1.333
ICU stay	> 2 to 7 days vs 0-2 days	0.1068	1.178	0.965	1.439
	> 7 days vs 0-2 days	<.0001	2.000	1.601	2.498
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.5915	1.024	0.938	1.118
ATB with hospitalization	Yes vs No	0.7785	1.022	0.879	1.189
<i>Post resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.0001	1.201	1.093	1.321
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.305	1.192	1.428
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	1.675	1.395	2.011
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.210	1.113	1.315
Age	50 to 69 vs <50	0.7850	1.021	0.879	1.186
	70-79 vs <50	0.2585	1.096	0.935	1.286
	≥ 80 vs <50	<.0001	1.500	1.251	1.797
Charlson	1 à 2 vs 0	0.3216	1.050	0.953	1.157
	≥ 3 vs 0	0.2074	1.113	0.942	1.314
Malnutrition	Yes vs No	0.0043	1.190	1.056	1.340
ICU stay	> 2 to 7 days vs 0-2 days	0.1331	1.165	0.954	1.423
	> 7 days vs 0-2 days	<.0001	1.864	1.491	2.332
<i>Pre resection ATB exposure</i>					
ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant	0.4730	0.967	0.882	1.060
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB	0.5350	1.204	0.670	2.164

	ATB during neoadjuvant vs Neoadjuvant/no ATB	0.0706	1.353	0.975	1.878
ATB with hospitalization	Yes vs No	0.8349	0.984	0.846	1.145
<i>Post resection ATB exposure</i>					
ATB outside chemotherapy	Yes vs No	0.0256	1.164	1.019	1.330
ATB during chemotherapy	Yes vs No	<.0001	1.224	1.110	1.350
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.300	1.188	1.423
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	1.710	1.423	2.053
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.246	1.146	1.355
Age	50 to 69 vs <50	0.7386	1.026	0.883	1.192
	70-79 vs <50	0.2924	1.090	0.929	1.278
	≥ 80 vs <50	<.0001	1.493	1.246	1.789
Charlson	1 à 2 vs 0	0.4734	1.036	0.940	1.142
	≥ 3 vs 0	0.2064	1.113	0.942	1.315
Malnutrition	Yes vs No	0.0032	1.197	1.062	1.349
ICU stay	> 2 to 7 days vs 0-2 days	0.1384	1.164	0.952	1.422
	> 7 days vs 0-2 days	<.0001	1.840	1.470	2.302
<i>Pre resection ATB exposure</i>					
ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant	0.2836	0.950	0.866	1.043
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB	0.5895	1.176	0.653	2.117
	ATB during neoadjuvant vs Neoadjuvant/no ATB	0.1936	1.244	0.895	1.728
ATB with hospitalization	Yes vs No	0.9269	0.993	0.853	1.156
<i>Post resection ATB exposure</i>					
C3G	Yes vs No	0.0099	1.203	1.045	1.385
Antifungal – Others	Yes vs No	0.0289	1.126	1.012	1.253
Antifungal – Azoles	Yes vs No	0.5483	1.043	0.910	1.194
Beta-lactamines – Others	Yes vs No	0.1369	0.855	0.696	1.051
Penicillin A	Yes vs No	0.1637	1.079	0.969	1.201
Penicillin A + beta-lactamase inhibitor	Yes vs No	0.6340	1.024	0.930	1.127
Macrolides	Yes vs No	0.4734	0.944	0.806	1.105
Metronidazole based-antibiotherapies	Yes vs No	0.0590	0.877	0.766	1.005
Quinolones	Yes vs No	0.0093	1.139	1.033	1.257
Streptogramins	Yes vs No	0.0240	1.229	1.027	1.470
Other ATB including cyclins	Yes vs No	<.0001	1.490	1.310	1.695
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.283	1.171	1.405
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	1.639	1.361	1.972

6C-Localized rectum/junction cancer (N=5,097)

Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.338	1.214	1.475
Age	50 to 69 vs <50	0.6873	1.056	0.809	1.379
	70-79 vs <50	0.0292	1.354	1.031	1.777
	≥ 80 vs <50	<.0001	1.877	1.434	2.458
Charlson	1 à 2 vs 0	0.0287	1.130	1.013	1.260
	≥ 3 vs 0	<.0001	1.448	1.249	1.678
Malnutrition	Yes vs No	0.0025	1.249	1.081	1.444
ICU stay	> 2 to 7 days vs 0-2 days	0.0090	1.301	1.068	1.585
	> 7 days vs 0-2 days	<.0001	1.880	1.543	2.291
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.6897	0.979	0.883	1.086
ATB with hospitalization	Yes vs No	0.7470	1.032	0.854	1.246
<i>Post resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.4120	0.957	0.861	1.063
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.845	1.664	2.047
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	2.437	1.962	3.027
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.328	1.204	1.464
Age	50 to 69 vs <50	0.6336	1.067	0.817	1.393
	70-79 vs <50	0.0211	1.378	1.049	1.809
	≥ 80 vs <50	<.0001	1.909	1.457	2.500
Charlson	1 à 2 vs 0	0.0440	1.119	1.003	1.249
	≥ 3 vs 0	<.0001	1.443	1.243	1.674
Malnutrition	Yes vs No	0.0020	1.256	1.087	1.451
ICU stay	> 2 to 7 days vs 0-2 days	0.0075	1.309	1.075	1.595
	> 7 days vs 0-2 days	<.0001	1.935	1.586	2.360
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.3461	0.951	0.858	1.055
ATB with hospitalization	Yes vs No	0.5880	1.054	0.872	1.274
<i>Post resection ATB exposure</i>					
C3G	Yes vs No	0.1946	1.136	0.937	1.378
Antifungal – Others	Yes vs No	0.6362	1.079	0.787	1.480
Antifungal – Azoles	Yes vs No	0.2869	1.208	0.853	1.711
Beta-lactamines – Others	Yes vs No	0.5748	0.919	0.684	1.235
Penicillin A	Yes vs No	0.6333	0.966	0.837	1.114
Penicillin A + beta-lactamase inhibitor	Yes vs No	0.0070	1.200	1.051	1.370

Macrolides	Yes vs No	0.0267	0.788	0.638	0.973
Metronidazole based-antibiotherapies	Yes vs No	0.8949	0.989	0.839	1.166
Quinolones	Yes vs No	0.9377	1.005	0.882	1.146
Streptogramins	Yes vs No	0.2027	0.843	0.649	1.096
Other ATB including cyclins	Yes vs No	0.4060	1.077	0.904	1.284
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.784	1.605	1.983
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	2.337	1.877	2.910

6D-Advanced rectum/junction cancer patients (N=6,859)

Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.148	1.072	1.229
Age	50 to 69 vs <50	0.4649	0.957	0.850	1.077
	70-79 vs <50	0.7972	0.983	0.864	1.119
	≥ 80 vs <50	0.0941	1.132	0.979	1.309
Charlson	1 à 2 vs 0	0.0959	1.068	0.988	1.153
	≥ 3 vs 0	0.3683	1.068	0.926	1.231
Malnutrition	Yes vs No	0.0009	1.170	1.067	1.284
ICU stay	> 2 to 7 days vs 0-2 days	0.3122	0.920	0.783	1.081
	> 7 days vs 0-2 days	0.0192	1.238	1.035	1.481
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.0735	1.065	0.994	1.141
ATB with hospitalization	Yes vs No	0.8750	0.989	0.861	1.136
<i>Post resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.1026	1.062	0.988	1.142
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.269	1.182	1.363
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	1.642	1.438	1.877
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	0.0004	1.133	1.058	1.213
Age	50 to 69 vs <50	0.6802	0.975	0.866	1.098
	70-79 vs <50	0.6609	1.029	0.904	1.172
	≥ 80 vs <50	0.0005	1.303	1.124	1.510
Charlson	1 à 2 vs 0	0.0353	1.086	1.006	1.174
	≥ 3 vs 0	0.1816	1.102	0.956	1.271
Malnutrition	Yes vs No	0.0021	1.156	1.054	1.268
ICU stay	> 2 to 7 days vs 0-2 days	0.2898	0.917	0.780	1.077
	> 7 days vs 0-2 days	0.0114	1.260	1.053	1.506
<i>Pre resection ATB exposure</i>					

ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant	0.2816	1.071	0.945	1.214
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB	0.3115	0.943	0.842	1.056
	ATB during neoadjuvant vs Neoadjuvant/no ATB	0.0089	1.132	1.032	1.242
ATB with hospitalization	Yes vs No	0.9170	1.007	0.877	1.157
<i>Post resection ATB exposure</i>					
ATB outside chemotherapy	Yes vs No	0.1353	0.939	0.865	1.020
ATB during chemotherapy	Yes vs No	<.0001	1.312	1.202	1.432
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.257	1.170	1.351
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	1.604	1.403	1.833
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.147	1.071	1.229
Age	50 to 69 vs <50	0.6087	0.969	0.861	1.092
	70-79 vs <50	0.9365	1.005	0.883	1.145
	≥ 80 vs <50	0.0060	1.229	1.061	1.423
Charlson	1 à 2 vs 0	0.0602	1.077	0.997	1.164
	≥ 3 vs 0	0.3099	1.077	0.934	1.242
Malnutrition	Yes vs No	0.0015	1.162	1.059	1.275
ICU stay	> 2 to 7 days vs 0-2 days	0.1941	0.899	0.765	1.056
	> 7 days vs 0-2 days	0.0199	1.237	1.034	1.480
<i>Pre resection ATB exposure</i>					
ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant	0.4313	1.052	0.927	1.195
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB	0.1330	0.917	0.819	1.027
	ATB during neoadjuvant vs Neoadjuvant/no ATB	0.0294	1.109	1.010	1.218
ATB with hospitalization	Yes vs No	0.9935	1.001	0.871	1.149
<i>Post resection ATB exposure</i>					
C3G	Yes vs No	0.0008	1.223	1.088	1.376
Antifungal – Others	Yes vs No	0.1863	1.083	0.962	1.219
Antifungal – Azoles	Yes vs No	0.0021	1.236	1.080	1.415
Beta-lactamines – Others	Yes vs No	0.8044	1.023	0.852	1.230
Penicillin A	Yes vs No	0.5429	0.970	0.881	1.069
Penicillin A + beta-lactamase inhibitor	Yes vs No	0.4198	1.035	0.952	1.126
Macrolides	Yes vs No	0.6294	0.964	0.831	1.119
Metronidazole based-antibiotherapies	Yes vs No	0.0604	1.104	0.996	1.224
Quinolones	Yes vs No	0.3096	0.959	0.885	1.039
Streptogramins	Yes vs No	0.0665	1.166	0.990	1.375
Other ATB including cyclins	Yes vs No	0.0001	1.234	1.109	1.372
ATB with hospitalization ≤ 30 days after resection	Yes vs No	<.0001	1.232	1.146	1.325
ATB with hospitalization > 30 days after resection	Yes vs No	<.0001	1.542	1.347	1.766

Supplementary Table 7. Distribution of death and recurrence according to antibiotic intake.

	Localized colon cancer n=17 735		Advanced colon cancer n=5 805		Localized rectum/junction cancer n=5 097		Advanced rectum/junction cancer n=6 859		Total n=35 496	
	n	%	n	%	n	%	n	%	n	%
No ATB intake	4 094		964		1 240		1 281		7 577	
no recurrence	2 891	70.6	623	64.6	858	69.2	609	47.5	4 979	65.7
recurrence or death	1 203	29.4	341	35.4	382	30.8	672	52.5	2 598	34.3
recurrence	764	18.7	320	33.2	288	23.2	624	48.7	1 996	26.3
death	439	10.7	21	2.2	94	7.6	48	3.7	602	7.9
of which death at 2 months	254	6.2	4	0.4	48	3.9	34	2.7	340	4.5
Only hospital	1 862		418		465		585		3 330	
no recurrence	854	45.9	206	49.3	187	40.2	217	37.1	1 464	44.0
recurrence or death	1 008	54.1	212	50.7	278	59.8	368	62.9	1 866	56.0
recurrence	446	24.0	179	42.8	169	36.3	292	49.9	1 086	32.6
death	562	30.2	33	7.9	109	23.4	76	13.0	780	23.4
of which death at 2 months	368	19.8	11	2.6	71	15.3	38	6.5	488	14.7
Only city pharmacy	7 025		2 692		2 124		2 752		14 593	
no recurrence	5 298	75.4	1 702	63.2	1 585	74.6	1 456	52.9	10 041	68.8
recurrence or death	1 727	24.6	990	36.8	539	25.4	1 296	47.1	4 552	31.2
recurrence	1 249	17.8	940	34.9	455	21.4	1 236	44.9	3 880	26.6
death	478	6.8	50	1.9	84	4.0	60	2.2	672	4.6
of which death at 2 months	191	2.7	10	0.4	35	1.6	19	0.7	255	1.7
Hospital and city pharmacy	4 754		1 733		1 268		2 241		9 996	
no recurrence	2 930	61.6	925	53.4	724	57.1	928	41.4	5 507	55.1
recurrence or death	1 824	38.4	808	46.6	544	42.9	1 313	58.6	4 489	44.9
recurrence	1 094	23.0	748	43.2	415	32.7	1 221	54.5	3 478	34.8
death	730	15.4	60	3.5	129	10.2	92	4.1	1 011	10.1
of which death at 2 months	312	6.6	11	0.6	52	4.1	27	1.2	402	4.0

Supplementary Table 8. Distribution of death and recurrence according to antibiotic intake 2 months after resection.

	No hospitalization for infection n=22 199		Hospitalization for infection n=13 297		p-value
	n	%	n	%	
Sex:					<0,0001
Male	11 310	51.0	7 250	54.4	
Female	10 860	49.0	6 076	45.6	
Age, years:					<0,0001
18-49	1 536	6.9	817	6.1	
50-69	9 878	44.6	4 935	37.0	
70-79	5 697	25.7	3 467	26.0	
≥ 80	5 059	22.8	4 107	30.8	
Malnutrition:					<0,0001
No	20 278	91.5	10 968	82.3	
Yes	1 892	8.5	2 358	17.7	
Charlson comorbidities:					<0,0001
0	14 878	67.1	7 834	58.8	
1-2	5 645	25.5	3 781	28.4	
≥ 3	1 647	7.4	1 711	12.8	
Length of stay in intensive care unit, days:					<0,0001
0-2	21 286	96.0	11 551	86.7	
2-7	651	2.9	824	6.2	
> 7	233	1.1	951	7.1	

Supplementary Table 9. Multivariate analyses for 3-year DFS of patients with resected colorectal cancer according to antibiotic and chemotherapy exposure.

9A-Localized colon cancer patients (n=11,140)

Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1	1.111	1.289
Age	50 to 69 vs <50	0.2501	1.135	0.915	1.409
	70-79 vs <50	0.0009	1.446	1.162	1.798
	≥ 80 vs <50	<.0001	2.498	2.018	3.092
Charlson	1 à 2 vs 0	<.0001	1.223	1.125	1.330
	≥ 3 vs 0	<.0001	1.700	1.527	1.893
Malnutrition	Yes vs No	<.0001	1.526	1.373	1.697
ICU stay	> 2 to 7 days vs 0-2 days	<.0001	1.480	1.231	1.779
	> 7 days vs 0-2 days	<.0001	2.179	1.702	2.789
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.8253	1.009	0.932	1.093
<i>Post resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.0169	1.105	1.018	1.199
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.194	1.108	1.287
Age	50 to 69 vs <50	0.2476	1.136	0.915	1.411
	70-79 vs <50	0.0009	1.450	1.165	1.803
	≥ 80 vs <50	<.0001	2.501	2.020	3.096
Charlson	1 à 2 vs 0	<.0001	1.221	1.123	1.328
	≥ 3 vs 0	<.0001	1.696	1.523	1.889
Malnutrition	Yes vs No	<.0001	1.522	1.368	1.692
ICU stay	> 2 to 7 days vs 0-2 days	<.0001	1.470	1.223	1.768
	> 7 days vs 0-2 days	<.0001	2.145	1.675	2.746
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.9421	1.003	0.926	1.086
<i>Post resection ATB exposure</i>					
C3G	Yes vs No	0.7560	0.977	0.843	1.132
Antifungal – Others	Yes vs No	0.1525	1.189	0.938	1.506
Antifungal – Azoles	Yes vs No	0.0050	1.446	1.118	1.870
Beta-lactamines – Others	Yes vs No	0.5139	1.069	0.876	1.304
Penicillin A	Yes vs No	0.6623	0.976	0.876	1.088
Penicillin A + beta-lactamase inhibitor	Yes vs No	0.0127	1.149	1.030	1.282
Macrolides	Yes vs No	0.2413	0.913	0.785	1.063
Metronidazole based-antibiotherapies	Yes vs No	0.7275	1.026	0.887	1.188
Quinolones	Yes vs No	0.0087	1.160	1.038	1.297
Streptogramins	Yes vs No	0.1000	1.183	0.968	1.444
Other ATB including cyclins	Yes vs No	0.9900	0.999	0.856	1.167

9B-Advanced colon cancer patients (n=5,805)

Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	0.0010	1.203	1.078	1.343
Age	50 to 69 vs <50	0.0616	1.221	0.990	1.506
	70-79 vs <50	0.0498	1.248	1.000	1.558
	≥ 80 vs <50	0.0002	1.600	1.246	2.055
Charlson	1 à 2 vs 0	0.0592	1.129	0.995	1.281
	≥ 3 vs 0	0.9492	0.992	0.775	1.270
Malnutrition	Yes vs No	0.0110	1.256	1.054	1.496
ICU stay	> 2 to 7 days vs 0-2 days	0.9385	1.014	0.720	1.427
	> 7 days vs 0-2 days	0.0236	1.769	1.080	2.899
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.5452	1.036	0.924	1.163
<i>Post resection ATB exposure</i>					
ATB as outpatient	Yes vs No	<.0001	1.280	1.134	1.446
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	0.0011	1.200	1.075	1.340
Age	50 to 69 vs <50	0.0900	1.199	0.972	1.479
	70-79 vs <50	0.0499	1.249	1.000	1.560
	≥ 80 vs <50	0.0002	1.619	1.259	2.081
Charlson	1 à 2 vs 0	0.0426	1.139	1.004	1.293
	≥ 3 vs 0	0.4683	0.912	0.710	1.171
Malnutrition	Yes vs No	0.0067	1.275	1.070	1.519
ICU stay	> 2 to 7 days vs 0-2 days	0.9899	1.002	0.712	1.412
	> 7 days vs 0-2 days	0.0186	1.810	1.104	2.968
<i>Pre resection ATB exposure</i>					
ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant	0.7760	0.983	0.870	1.109
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB	0.6663	1.169	0.575	2.375
	ATB during neoadjuvant vs Neoadjuvant/no ATB	0.6971	1.091	0.703	1.694
<i>Post resection ATB exposure</i>					
ATB outside chemotherapy	Yes vs No	0.0361	1.213	1.013	1.453
ATB during chemotherapy	Yes vs No	<.0001	1.317	1.162	1.493
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	0.0001	1.241	1.111	1.387
Age	50 to 69 vs <50	0.0839	1.203	0.976	1.484
	70-79 vs <50	0.0639	1.234	0.988	1.541
	≥ 80 vs <50	0.0002	1.615	1.255	2.077
Charlson	1 à 2 vs 0	0.0292	1.151	1.014	1.307

	≥ 3 vs 0		0.6057	0.936	0.728	1.203
Malnutrition	Yes vs No		0.0045	1.291	1.082	1.539
ICU stay	> 2 to 7 days vs 0-2 days		0.8561	0.969	0.687	1.365
	> 7 days vs 0-2 days		0.0107	1.908	1.161	3.133
<i>Pre resection ATB exposure</i>						
ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant		0.6138	0.969	0.857	1.095
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB		0.7539	1.121	0.550	2.284
	ATB during neoadjuvant vs Neoadjuvant/no ATB		0.9516	0.986	0.632	1.539
<i>Post resection ATB exposure</i>						
C3G	Yes vs No		0.0290	1.252	1.023	1.531
Antifungal – Others	Yes vs No		0.0056	1.217	1.059	1.398
Antifungal – Azoles	Yes vs No		0.4257	0.926	0.768	1.118
Beta-lactamines – Others	Yes vs No		0.2256	0.831	0.615	1.121
Penicillin A	Yes vs No		0.2399	1.088	0.945	1.252
Penicillin A + beta-lactamase inhibitor	Yes vs No		0.7275	1.024	0.895	1.173
Macrolides	Yes vs No		0.8848	0.985	0.803	1.209
Metronidazole based-antibiotherapies	Yes vs No		0.6575	1.044	0.864	1.261
Quinolones	Yes vs No		0.0411	1.157	1.006	1.331
Streptogramins	Yes vs No		0.5780	1.079	0.826	1.409
Other ATB including cyclins	Yes vs No		<.0001	1.553	1.299	1.856

9C-Localized rectum/junction cancer (N=3,364)

Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	<.0001	1.425	1.248	1.628
Age	50 to 69 vs <50	0.5045	1.125	0.797	1.588
	70-79 vs <50	0.0076	1.617	1.136	2.301
	≥ 80 vs <50	<.0001	2.268	1.596	3.224
Charlson	1 à 2 vs 0	0.1901	1.107	0.951	1.288
	≥ 3 vs 0	0.0126	1.340	1.065	1.686
Malnutrition	Yes vs No	0.0015	1.448	1.152	1.820
ICU stay	> 2 to 7 days vs 0-2 days	0.4724	1.133	0.807	1.590
	> 7 days vs 0-2 days	0.2320	1.316	0.839	2.064
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.8955	1.010	0.875	1.164
<i>Post resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.5181	1.049	0.908	1.212
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	95% Hazard Ratio		

			Hazard Ratio	Confidence Limits	
Sex	Male vs Female	<.0001	1.442	1.261	1.650
Age	50 to 69 vs <50	0.4666	1.137	0.805	1.605
	70-79 vs <50	0.0065	1.632	1.147	2.323
	≥ 80 vs <50	<.0001	2.301	1.618	3.271
Charlson	1 à 2 vs 0	0.2987	1.084	0.931	1.263
	≥ 3 vs 0	0.0146	1.333	1.058	1.679
Malnutrition	Yes vs No	0.0012	1.462	1.163	1.839
ICU stay	> 2 to 7 days vs 0-2 days	0.5158	1.119	0.797	1.572
	> 7 days vs 0-2 days	0.2444	1.308	0.832	2.057
<i>Pre resection ATB exposure</i>					
ATB as outpatient	Yes vs No	0.6528	0.967	0.838	1.117
<i>Post resection ATB exposure</i>					
C3G	Yes vs No	0.6601	1.070	0.792	1.445
Antifungal – Others	Yes vs No	0.4697	1.213	0.718	2.050
Antifungal – Azoles	Yes vs No	0.7559	1.098	0.610	1.973
Beta-lactamines – Others	Yes vs No	0.4107	0.833	0.539	1.288
Penicillin A	Yes vs No	0.7019	1.039	0.854	1.264
Penicillin A + beta-lactamase inhibitor	Yes vs No	0.0223	1.255	1.033	1.525
Macrolides	Yes vs No	0.9791	1.003	0.773	1.303
Metronidazole based-antibiotherapies	Yes vs No	0.7444	0.962	0.760	1.217
Quinolones	Yes vs No	0.0223	1.258	1.033	1.532
Streptogramins	Yes vs No	0.9792	1.005	0.700	1.443
Other ATB including cyclins	Yes vs No	0.2360	1.174	0.900	1.531

9D-Advanced rectum/junction cancer patients (N=4,034)


Analysis of Maximum Likelihood Estimates						
Parameter			Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female		0.0021	1.155	1.054	1.266
Age	50 to 69 vs <50		0.7527	0.975	0.834	1.140
	70-79 vs <50		0.8535	0.984	0.828	1.169
	≥ 80 vs <50		0.0348	1.238	1.015	1.509
Charlson	1 à 2 vs 0		0.7465	1.018	0.913	1.135
	≥ 3 vs 0		0.8708	1.018	0.823	1.259
Malnutrition	Yes vs No		0.0076	1.215	1.053	1.402
ICU stay	> 2 to 7 days vs 0-2 days		0.1464	0.838	0.660	1.064
	> 7 days vs 0-2 days		0.8236	0.950	0.603	1.495
<i>Pre resection ATB exposure</i>						
ATB as outpatient	Yes vs No		0.6389	1.023	0.930	1.125
<i>Post resection ATB exposure</i>						
ATB as outpatient	Yes vs No		0.1004	1.083	0.985	1.191
Analysis of Maximum Likelihood Estimates						
Parameter			Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	

Sex	Male vs Female	0.0072	1.135	1.035	1.244
Age	50 to 69 vs <50	0.9004	0.990	0.847	1.158
	70-79 vs <50	0.7987	1.023	0.860	1.216
	≥ 80 vs <50	0.0005	1.423	1.165	1.739
Charlson	1 à 2 vs 0	0.3990	1.048	0.940	1.168
	≥ 3 vs 0	0.7149	1.040	0.841	1.287
Malnutrition	Yes vs No	0.0178	1.189	1.030	1.371
ICU stay	> 2 to 7 days vs 0-2 days	0.1287	0.831	0.655	1.055
	> 7 days vs 0-2 days	0.9471	0.985	0.626	1.550
<i>Pre resection ATB exposure</i>					
ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant	0.5251	1.057	0.891	1.255
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB	0.1612	0.895	0.765	1.045
	ATB during neoadjuvant vs Neoadjuvant/no ATB	0.1880	1.091	0.958	1.242
<i>Post resection ATB exposure</i>					
ATB outside chemotherapy	Yes vs No	0.1082	0.910	0.811	1.021
ATB during chemotherapy	Yes vs No	<.0001	1.412	1.259	1.584
Analysis of Maximum Likelihood Estimates					
Parameter		Pr > ChiSq	Hazard Ratio	95% Hazard Ratio Confidence Limits	
Sex	Male vs Female	0.0028	1.151	1.050	1.263
Age	50 to 69 vs <50	0.8441	0.984	0.841	1.152
	70-79 vs <50	0.9839	1.002	0.842	1.192
	≥ 80 vs <50	0.0042	1.339	1.097	1.635
Charlson	1 à 2 vs 0	0.5948	1.030	0.924	1.149
	≥ 3 vs 0	0.6795	1.046	0.845	1.294
Malnutrition	Yes vs No	0.0137	1.197	1.038	1.382
ICU stay	> 2 to 7 days vs 0-2 days	0.1006	0.818	0.644	1.040
	> 7 days vs 0-2 days	0.8184	0.948	0.602	1.493
<i>Pre resection ATB exposure</i>					
ATB as outpatient	ATB/no neoadjuvant vs no ATB/no neoadjuvant	0.9659	0.996	0.837	1.186
Timing of chemotherapy and antibiotherapy	ATB outside neoadjuvant vs Neoadjuvant/no ATB	0.0295	0.840	0.719	0.983
	ATB during neoadjuvant vs Neoadjuvant/no ATB	0.5389	1.042	0.914	1.187
<i>Post resection ATB exposure</i>					
C3G	Yes vs No	0.0519	1.206	0.998	1.458
Antifungal – Others	Yes vs No	0.4835	1.061	0.899	1.252
Antifungal – Azoles	Yes vs No	0.0768	1.182	0.982	1.422
Beta-lactamines – Others	Yes vs No	0.2122	1.190	0.905	1.564
Penicillin A	Yes vs No	0.8288	1.015	0.885	1.164
Penicillin A + beta-lactamase inhibitor	Yes vs No	0.0607	1.125	0.995	1.271
Macrolides	Yes vs No	0.5720	0.943	0.769	1.156
Metronidazole based-antibiotherapies	Yes vs No	0.0132	1.204	1.040	1.395
Quinolones	Yes vs No	0.8391	1.012	0.900	1.138
Streptogramins	Yes vs No	0.3152	1.134	0.887	1.450
Other ATB including cyclins	Yes vs No	<.0001	1.402	1.197	1.643

Supplementary Figure 1. Distribution of the number of chemotherapy cycles according to antibiotic intake in the groups of patients receiving at least one adjuvant chemotherapy cycle (N=9,205).

N.B: In France, when reimbursing the cost of chemotherapy, a 2-day treatment such as LV5FU2 or FOLFOX is considered to be 2 cycles if the patient goes to the hospital on both days (D1 and D2). This can explain why some patients receive more than the usual 12 cycles of chemotherapy in the adjuvant setting.

	No antibiotic	Antibiotic
Min	1	1
Q ₁	11	11
Median	12	12
Q ₃	22	24
Max	155	203



Supplementary Figure 2. Three-year disease-free survival of resected colorectal cancer patients according to the primitive location and stage.

Univariate 3-year disease-free survival assessing the impact of the primitive location and stage (N=35,496).

